Skip to main content

Navigation group

Type at least 3 characters
1,352 articles

Articles

Original Research

Published on 27 Jun 2024

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)

in Thyroid Endocrinology

  • Sophie Leboulleux
  • Ellen Kapiteijn
  • Saskia Litière
  • Patrick Schöffski
  • Yann Godbert
  • Patrice Rodien
  • Barbara Jarzab
  • Domenico Salvatore
  • Sylvie Zanetta
  • Jaume Capdevila
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)
Frontiers in Endocrinology
doi 10.3389/fendo.2024.1403687
  • 414 views